New startup ideas · Health and bio · Healthcare and bio
startup idea
Corpus Bio
The pooled experiment exchange that teaches drug-discovery models what failed.
Corpus Bio sells pharma and biotech R&D organizations a subscription platform that captures every wet-lab experiment - including the roughly 90 percent that fail and never leave the notebook - in a structured, model-readable format.
- Software subscription
- Enterprise
- $100B+ market
- Creates a new category
- Global from day one
4/5
venture judge
5
similar startups, last 2 years (11 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$2,000 · 5 weeks · 15 prospects
For $2,000 in 5 weeks, prove that venture-backed biotechs will get legal clearance to pool anonymized failed expression runs and pay $2,500 deposits before the pool exists.
Riskiest assumption · Legal counsel at a venture-backed biotech will approve contributing anonymized failed protein-expression data to a shared pool within two weeks, and the science lead will pay before the pool has critical mass.
1Focus group: who and where
Head of protein science or platform lead at a venture-backed biotech (Series A to C, 20-150 people, Boston-Cambridge or South San Francisco) running 50 or more expression constructs a quarter, whose team keeps repeating failed constructs because outcomes are buried in unsearchable ELN entries.
where to find 15 · The Bits in Bio Slack community, the published resident-company directories of LabCentral and BioLabs, warm introductions through the prospects' seed and Series A investors, and the PEGS Boston protein engineering summit speaker and alumni network.
2Sell first, build later
A founding data-partner pilot, capped at 10 biotechs: contribute anonymized protein-expression outcomes under the cleared one-page terms and receive quarterly priors on which constructs, tags, and conditions will fail, first report within 60 days of data transfer.
the ask · $7,500 per quarter per company, with $2,500 invoiced up front on signature
a real yes · A real yes is a paid $2,500 invoice plus a countersigned data-contribution agreement; cleared legal terms without payment, enthusiasm from scientists whose counsel never responds, and requests for a free trial are noes.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Legal clearance of sharing terms
$1,200 · 21 days
Have a life-science attorney draft a one-page anonymized data-contribution term sheet: what fields leave the building, how anonymization works, what members get back. Send it to 12 heads of protein science recruited through Bits in Bio and the LabCentral directory and ask each to run it past their counsel within 14 days. The deliverable is redlines or signatures, not opinions.
keep going if · 5 of 12 companies return the term sheet legally cleared or signed within 14 days of receiving it
2. Blind prior benchmark
$300 · 14 days
Under mutual CDAs, collect roughly 25 historical expression outcomes from each of 6 labs. Hand-build priors on which tags, hosts, and conditions fail, then predict outcomes on 15 held-out constructs per lab, scored against the lab's own scientists' predictions. This tests whether pooled failures beat internal intuition at all.
keep going if · Pooled priors beat the lab's own scientists' predictions on held-out constructs at 4 of 6 labs
3. Founding-partner deposit pre-sale
$500 · 14 days
Pitch the 10 most engaged prospects a founding data-partner pilot in person over Cambridge and SSF coffee meetings: quarterly priors on their live construct queue, their assay class prioritized, $7,500 per quarter with $2,500 invoiced on signature. A founder runs every pitch with the benchmark results in hand.
keep going if · 3 of 10 pitched companies pay the $2,500 invoice within 14 days of the pitch
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$2,500
per prospect, refundable
how · A $2,500 invoice paid on signature of the pilot agreement, credited to the first quarter - the standard instrument for a paid enterprise design-partner pilot, and the only proof that both the science lead and the budget owner have moved. The head of protein science signs the pilot; counsel countersigns the data-contribution terms. set up: Stripe Invoicing ↗
what it reserves · One of 10 founding data-partner slots, the $7,500 quarterly rate locked through year one, and priority for their assay class in the first prior models
refund · Fully refundable until the first pooled-prior report is delivered, expected within 60 days of the company's data transfer.
target · 3 paid $2,500 deposits from 10 pitches within 35 days
Go: build it if
5 of 12 term sheets legally cleared within two weeks each, priors beating internal predictions at 4 of 6 labs, and 3 paid $2,500 deposits - the legal gate opens and the pool pays; build the capture layer.
Kill: stop if
2 or fewer legal clearances from 12 asks after 3 weeks, or 0 paid deposits from 10 pitches despite winning benchmarks - counsel is the wall the stated risk predicted; stop.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
If your protein team is like most, about half of your failed expression runs repeat a failure a lab down the street already hit - and none of it ever leaves anyone's ELN. I'm building Corpus Bio: ten founding biotechs pool anonymized expression outcomes and get back priors on which constructs, tags, and conditions actually fail. I have a one-page data-sharing term sheet your counsel can clear in a week. Worth 20 minutes to see whether last quarter's failures would have been predictable?
landing page
Stop rerunning expression failures ten other labs already made $7,500 per quarter, $2,500 today: a founding data-partner slot, pooled priors on protein expression, one-page legal terms your counsel can clear in a week Reserve one of 10 founding slots - $2,500, credited to your first quarter
deposit terms
The $2,500 payment reserves one of 10 founding data-partner slots and is credited in full to your first $7,500 quarter. It is fully refundable until we deliver your first pooled-prior report, expected within 60 days of your data transfer. Your rate stays $7,500 per quarter through year one.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
87
Idea Score, 0-100 · raw 54.4 x 1.61
Active
competition: more crowded than 56% of ideas · headwind x0.72
+4.3
government priorities, secondary (70 matching grants)
Trend
77
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)90
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst50
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
84
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive81
- Technologist judge75
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were pooled, experiment, exchange, teaches, drug-discovery, models, failed, corpus.
The idea in full
- What
- Corpus Bio sells pharma and biotech R&D organizations a subscription platform that captures every wet-lab experiment - including the roughly 90 percent that fail and never leave the notebook - in a structured, model-readable format. Members contribute anonymized assay outcomes to a shared corpus and in return get predictive priors trained on the pooled data: which constructs express, which assays are artifact-prone, which conditions waste a week. Distribution runs through lab instrument vendors and CROs who bundle the capture layer; the software makes no clinical claims and faces no regulator.
- Why now
- 'Drug discovery' is the cluster's most crowded phrase at 5 companies, and the S26/X26 batches (Rasyn's general intelligence for chemistry, WonderTx's extrapolative AI, Omanta's research lab for one) are all model builders starved for exactly the experimental data no one shares - while the graveyard's Great Bay Bio died attacking 'long timelines, high costs, and low success rates' with models alone. The data layer under the crowd is empty.
- Wedge: first customer and entry point
- Ten venture-backed biotechs on the same instrument vendor's channel, starting with protein-expression outcomes - a narrow assay class where pooled failure data pays back within one quarter of avoided repeats.
- Path to 100x
- Global pharma R&D spend runs in the hundreds of billions a year, and a platform whose priors reliably kill doomed experiments early prices against that spend, not against software budgets. The exchange compounds like a network, not a database: every new member's failures improve every other member's models, so the first pool to reach critical mass becomes impossible to leave and unattractive to duplicate, which is how a new pre-competitive data category gets exactly one winner.
- Ceiling
- If the big instrument makers or a pharma consortium stand up a good-enough shared repository themselves, Corpus is reduced to a capture-tooling vendor without the pool that carries the value.
- Closest real companies, as the generator saw them
- Rasyn, WonderTx, and Atlas Discovery build predictive models and would be Corpus customers, not rivals; Omanta automates a single lab rather than pooling across labs; none operates a cross-company exchange.
- Main risk
- Pharma legal departments refuse to contribute even anonymized negative data, leaving the pool too shallow for the priors to beat each company's internal baseline.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Pooled failure data prices against hundreds of billions of R&D spend, and every member's failures make the pool harder to leave.
Bootstrapper
3/5
Software margins and a one-quarter payback on protein-expression repeats, but pharma legal review makes each contributing member a slow sale.
Operator
2/5
The product requires pharma legal to share failed-experiment data across competitors, which is the whole industry moving before value appears.
Technologist
4/5
Structuring the 90 percent of experiments that fail into model-readable priors is hard capture engineering whose value grows with every member's contributions.
Risk
3/5
Unregulated with no clinical claims, but distribution depends on instrument vendors and CROs who are also the most likely consortium competitor.
trends
3/5
Shares the real 2025-2026 data-scarcity shift behind the model-builder boom, but pharma legal resistance to pooling was equally blocking in 2023.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (pooled, experiment, exchange, teaches, drug-discovery, models, failed, corpus): 11 all-time, 5 from the last two years. Same matching as Idea Check.
Host a Poker Club and Make Money
Insurance risk layer for physical AI
Large-scale real-world robot & human data for embodied AI
Elnora is an AI co-pilot for biomedical lab protocols that learns from every experiment to accelerate drug discovery.
Reimagining how Machines Learn
AI powered holistic intelligence and workflow automation suite for Procurement & Supply Chain (P2P, S2C)
Recover failed subscription payments to increase retention and LTV
Developer of an online sports leagues and tournaments management application designed to track individual players' stats. The company's platform follows a multiple-tier revenue model based on subscriptions, commissions, advertising and monetization of big data, enabling customers to get a big enough pool of players, and enough data, to begin their scouting activities.
Foundation models and autonomous chambers for plant biology
AI-powered assistant for personal finances.
Class is a connection between people, the value of money, time and things.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
NIH / NIA · STTR phase I · $250K · posted 2026-09-23
- An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Diseaseawardhigh relevance
NIH / NIDDK · SBIR phase II · $1M · posted 2026-09-17
- JAML is a first-in-class cancer immunotherapy target for tissue-resident memory T cells.awardhigh relevance
NIH / NCI · SBIR phase II · $400K · posted 2026-09-14
- Selection of a Lead Candidate for the Development of an ASO Therapeutic for NF1 Cognitive and Social Deficitsawardhigh relevance
NIH / NINDS · SBIR phase I · $479K · posted 2026-09-01
- I-Corps: Translation potential of accurate acoustic digital twins for complex real-world environmentsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-20
- I-Corps: Translation Potential of a Hybrid Quantum-Classical Drug Discovery Platformawardhigh relevance
National Science Foundation · TIP-CHIPS KTA-3 Quantum · $50K · posted 2026-08-17
- InVitreON: A compact and integrated platform for long-term neuronal culture incubation, recording and closed-loop stimulationawardhigh relevance
NIH / NIMH · SBIR phase I · $457K · posted 2026-08-01
National Science Foundation · CSR-Computer Systems Research · $777K · posted 2026-07-27
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.